OR WAIT null SECS
- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2021 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Rheumatology Network's Top 5: September 3, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 3, 2021.
Rheumatoid Arthritis Quiz: COVID-19 Booster Dose
Booster doses of the COVID-19 vaccine are recommended for many patients with rheumatoid arthritis. Test your knowledge on who is eligible for a booster and how it should be administered with this quiz.
Click the image to view the story.
FDA Announces Black Box Warnings for Certain JAK Inhibitors
The move comes amid delays in FDA approvals for multiple JAK inhibitors for the treatment of rheumatic conditions.
Click the image to view the story.
Fibromyalgia Symptoms More Common in Patients With Postacute COVID-19 Syndrome
Clinical features of fibromyalgia are more common in participants who had postacute COVID-19 syndrome.
Click the image to view the story.
Patients With Polymyalgia Rheumatica Have Higher Rates of Long-term Glucocorticoid Use
“Although the international recommendations and the wide consensus that glucocorticoids should be used as shorter as possible (ideally by 1–2 years), a high rate of prolonged steroid treatment is still recorded in the management of PMR,” investigators stated.
Click the image to view the story.
Patients With Axial Spondyloarthritis Less Likely to Engage in Physical Activity
"Physical activity and exercise have been shown to improve general well-being and reduce cardiovascular disease risk in the general population," investigators stated. "Despite these recommendations, studies show that levels of PA are reduced among patients with axial spondyloarthritis.”
Click the image to view the story.
Related Content: